Cobicistat
Small molecule targets CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | TYBOST | — | 2015-11-25 – 2025-06-20 | fda.gov ↗ |
| Approved | EU (EMA) | Stribild | — | 2013-05-24 | europa.eu ↗ |
| Approved | US (FDA) | STRIBILD | — | 2012-08-27 | fda.gov ↗ |
Trials 65 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03858491 | Nov 2020 → Oct 2021 | non-small cell lung carcinoma | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 129 trials | ||||||
| Phase 1 | NCT06726382 | Dec 2024 → Apr 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06385119 | Apr → Dec 2024 | — | Fore Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05494866 | Dec 2022 → Mar 2024 | pancreatic ductal adenocarcinoma | German Cancer Research Center | Terminated | No outcome recorded |
| Phase 1 | NCT05692570 | Sep → Nov 2022 | — | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05458102 | Aug 2022 → May 2023 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT05197075 | Aug → Sep 2022 | HIV infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05378906 | Jun → Sep 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05236738 | May → Jul 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04718805 | Jan → Mar 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04661397 | Jan → Jul 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04263350 | Feb → Nov 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04322214 | Jan → Mar 2020 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 1 | NCT04208061 | Dec 2019 → Mar 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03864406 | Jun 2019 → Dec 2022 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT03094507 | Apr 2017 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT04069221 | Feb → May 2017 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02985996 | Feb → Nov 2017 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02984852 | Dec 2016 → Feb 2017 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02771249 | Jun 2016 → Aug 2021 | latent tuberculosis infection | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT02818348 | Jun → Oct 2016 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 1 | NCT02661373 | Mar 2016 → Mar 2018 | malaria | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02565888 | Nov 2015 → Jan 2016 | HIV infectious disease, hepatitis C virus infection | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02589158 | Nov 2015 → Mar 2016 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02475135 | Jun → Aug 2015 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1 | NCT02307656 | Dec 2014 → Sep 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02277600 | Nov 2014 → Jan 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02219217 | Oct 2014 → Jan 2015 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02203461 | Jul → Oct 2014 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT01896622 | Jun 2013 → Jan 2017 | HIV infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06014489 | Jan 2024 → Mar 2028 expected | acute myeloid leukemia | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT00892437 | May → Dec 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT02499978 | May → Jun 2016 | AIDS | Stanford University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02276612 | Dec 2014 → Nov 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02016924 | Jan 2014 → Jun 2025 overdue | AIDS | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01854775 | May 2013 → May 2020 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT04653194 | Sep 2020 → Jul 2023 | HIV infectious disease | Chelsea and Westminster NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT04252274 | Jan → Aug 2020 | COVID-19, pneumocystosis | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02707601 | Apr 2016 → Sep 2017 | HIV infectious disease, hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02616029 | Dec 2015 → Oct 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02269917 | Mar 2015 → Feb 2017 | HIV infectious disease | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 3 | NCT02071082 | Feb 2014 → Jan 2015 | HIV infectious disease, hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01533259 | Jan → Nov 2012 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01495702 | Dec 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01363011 | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01108510 | Apr 2010 → Nov 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00855335 | Apr 2009 → Aug 2016 | HIV infectious disease, pregnancy disorder | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT06337032 | Aug 2024 → Mar 2034 expected | HIV infectious disease | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT05748093 | Apr 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05078671 | Dec 2021 → Dec 2025 | cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04388904 | Sep 2021 → Apr 2024 | HIV infectious disease | The Crofoot Research Center, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04442737 | Jul 2020 → Aug 2023 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT03683524 | Nov 2018 → Aug 2021 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 4 | NCT04225325 | May 2018 → Sep 2019 | HIV infectious disease | ADRIANO LAZZARIN, MD | Unknown | No outcome recorded |
| Phase 4 | NCT03693508 | Apr 2018 → May 2020 | HIV infectious disease, immunodeficiency disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT03447873 | Jun 2017 → Sep 2020 | HIV infectious disease | Hospitales Universitarios Virgen del Rocío | Completed | No outcome recorded |
| Phase 4 | NCT03163277 | May 2017 → Jun 2020 | HIV infectious disease, cognitive disorder | Giovanni Di Perri | Terminated | No outcome recorded |
| Phase 4 | NCT03123848 | Apr → May 2017 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 4 | NCT02503462 | Jul 2015 → Jan 2017 | AIDS dementia complex | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| Phase 4 | NCT02198443 | Jun 2015 → Jul 2016 | HIV infectious disease | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT02404233 | Mar 2015 → Sep 2016 | HIV infectious disease | Therapeutic Concepts | Unknown | No outcome recorded |
| Phase 4 | NCT02246998 | Dec 2014 → Jan 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01855867 | May 2013 → Apr 2014 | HIV infectious disease | Kenneth H. Mayer, MD | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03405194 | May 2018 → May 2020 | HIV infectious disease | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Withdrawn | No outcome recorded |
| — | NCT01929759 | Jan 2014 → Oct 2015 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 25 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07462559 Comparator | Mar → Dec 2026 expected | — | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05716854 Comparator | Mar → Jun 2023 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT04236453 Background | Jan → Apr 2020 | — | Janssen Pharmaceutica N.V., Belgium | Terminated | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04065399 Background | Nov 2019 → Dec 2027 expected | acute lymphoblastic leukemia, mixed phenotype acute leukemia | Syndax Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03251144 Background | Apr 2019 → Jul 2021 | AIDS, mitochondrial disease, poisoning | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT03480646 Background | Nov 2017 → Feb 2021 | castration-resistant prostate carcinoma | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06338826 Background | Feb 2025 → Sep 2027 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05729568 Background | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03045861 Background | Mar 2017 → Apr 2018 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01565850 Comparator | Apr 2012 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04475120 Comparator | Apr → Jul 2020 | COVID-19 | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06630299 Comparator | Oct 2024 → Apr 2026 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03227861 Background | Jul 2017 → Jan 2019 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02987530 Comparator | Apr 2017 → Jul 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02605954 Comparator | Nov 2015 → Jun 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02431247 Comparator | Jul 2015 → Mar 2017 | immunodeficiency disease | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01815736 Comparator | Mar 2013 → Mar 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07678268 Comparator | Jul 2025 → Jul 2026 overdue | HIV infectious disease | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT03842488 Comparator | Apr 2019 → Mar 2021 | HIV infectious disease | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Unknown | No outcome recorded |
| Phase 4 | NCT04064632 Background | Feb 2017 → Jun 2019 | HIV infectious disease | A.O. Ospedale Papa Giovanni XXIII | Unknown | No outcome recorded |
Press releases naming this drug 15 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-08-06 | Gilead Sciences | China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-11-23 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-11-05 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-10-22 | Gilead Sciences | Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV gilead.com ↗ |
| 2015-09-25 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2015-07-21 | Gilead Sciences | Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) gilead.com ↗ |
| 2014-04-21 | Gilead Sciences | Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA gilead.com ↗ |
| 2013-09-25 | Gilead Sciences | European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy gilead.com ↗ |
| 2013-04-29 | Gilead Sciences | Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat gilead.com ↗ |
| 2012-07-24 | Gilead Sciences | Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study gilead.com ↗ |
| 2012-06-28 | Gilead Sciences | Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat gilead.com ↗ |
| 2012-05-23 | Gilead Sciences | Gilead Files European Marketing Application for Boosting Agent Cobicistat gilead.com ↗ |
| 2011-12-05 | Gilead Sciences | Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study gilead.com ↗ |
| 2011-11-15 | Gilead Sciences | Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista(R) with Emtriva(R), GS 7340 and Cobicistat gilead.com ↗ |
| 2011-06-28 | Gilead Sciences | Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista(R) gilead.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 94 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cobicistat | “This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide...” NCT02707601 ↗89“The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance...” PMID 33315694 ↗ Apr 2021 “Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted...” NCT01815736 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based...” PMID 30169223 ↗ Jun 2017 “Cobicistat is a potent inhibitor of the CYP3A4 enzyme, which can significantly increase ketamine bioavailability and reduce interindividual variability by inhibiting ketamine's...” NCT07462559 ↗ “Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC...” NCT02431247 ↗ “A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults” NCT02071082 ↗ “Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.” NCT03693508 ↗ “Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food” NCT01495702 ↗ “To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.” NCT03447873 ↗ “Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.” NCT02985996 ↗ “A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.” NCT04442737 ↗ “Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC)” NCT03227861 ↗ “Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg” NCT04653194 ↗ “150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily” NCT02556268 ↗ “Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).” NCT04208061 ↗ “Cobicistat (COBI) is a mechanism-based inhibitor (MBI) of the cytochrome P450 (CYP)3A subfamily.” NCT05197075 ↗ “Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen” NCT01855867 ↗ “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily” NCT03251144 ↗ “darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)” NCT01565850 ↗ “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)” NCT02276612 ↗ “INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir” NCT06338826 ↗ “Bioequivalence of Darunavir 600 mg in the Presence of Cobicistat 90 mg” NCT05378906 ↗ “Cobicistat (COBI) 150 mg tablet administered orally once daily” NCT01108510 ↗ “Cobicistat (COBI) 150 mg tablet administered orally once daily” NCT00892437 ↗ “cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “elvitegravir (EVG; Vitekta®)/cobicistat (c; Tybost®)/TXF/FTC” NCT06630299 ↗ “Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF” NCT02246998 ↗ “ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC” NCT02605954 ↗ “darunavir 800 mg/cobicistat 150 mg once daily” NCT03094507 ↗ “pharmacologic booster cobicistat or ritonavir” NCT03631732 ↗ “darunavir/cobicistat 800/150 mg 1 cp/day” NCT04475120 ↗ “Cobicistat (COBI) is a pharmacoenhancer” PMID 25397568 ↗ Nov 2014 “ATV + cobicistat (COBI) or ATV/COBI FDC” NCT02469246 ↗ “atazanavir 300mg + cobicistat 150mg” NCT02589158 ↗ “ATV + cobicistat (COBI;Tybost®)” NCT02616783 ↗ “Darunavir/Cobicistat (FDC)” NCT00855335 ↗ |
| Known as | COBI | “Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC...” NCT02431247 ↗24“Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.” NCT03693508 ↗ “Darunavir (DRV), Emtricitabine/Tenofovir Alafenamide (F/TAF) and Cobicistat (COBI) tablet under fed condition on Day 1” NCT04661397 ↗ “Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).” NCT04208061 ↗ “Darunavir (DRV), emtricitabine (FTC), and tenofovir alafenamide (TAF) in the presence of cobicistat (COBI)” NCT04236453 ↗ “Cobicistat (COBI) is a mechanism-based inhibitor (MBI) of the cytochrome P450 (CYP)3A subfamily.” NCT05197075 ↗ “a regimen containing TDF without cobicistat (COBI) as ritonavir (RTV)-boosted atazanavir” NCT02246998 ↗ “The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure” NCT06014489 ↗ “Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.” PMID 23532097 ↗ Mar 2013 “A tablet containing cobicistat (COBI) 150 mg will be administered.” NCT02475135 ↗ “Cobicistat (COBI) 150 mg tablet administered orally once daily” NCT00892437 ↗ “cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).” NCT03683524 ↗ “Darunavir (DRV) in the presence of Cobicistat (COBI)” NCT05378906 ↗ “elvitegravir (EVG) boosted with cobicistat (COBI)” NCT01929759 ↗ “BMS-663068 with darunavir (DRV)/cobicistat (COBI)” NCT02277600 ↗ “ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC” NCT02605954 ↗ “ATV + cobicistat (COBI) or ATV/COBI FDC” NCT02469246 ↗ “ATV + cobicistat (COBI;Tybost®)” NCT02616783 ↗ “Cobicistat (COBI)” NCT02984852 ↗ |
| Known as | Cobicistat component of evotaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat component of genvoya | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat component of prezcobix | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat component of rezolsta | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat component of stribild | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat component of symtuza | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat on silicon dioxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Cobicistat, (r,r,s)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | GS-9350 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2095208 ↗ |
| Known as | Tybost | “elvitegravir (EVG; Vitekta®)/cobicistat (c; Tybost®)/TXF/FTC” NCT06630299 ↗3“ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC” NCT02605954 ↗ “ATV + cobicistat (COBI;Tybost®)” NCT02616783 ↗ “Cobisistat Tybost 150 mg” NCT07462559 ↗ |
| Action | Inhibit | “ritonavir and cobicistat, as inhibitors of P-gp” NCT01896622 ↗ |
| Modality | Small molecule | — CHEMBL2095208 ↗ |
| Route | Oral | “Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily” NCT00855335 ↗ |
| Target | CYP3A4 | “single-dose pharmacoboost approach using cobicistat to inhibit CYP3A4, thereby increasing exposure.” PMID 35598441 ↗ May 2022 |